The CMS has approved reimbursement for InSightec's initial tremor in 6 additional countries

[dani191]

The CMS has approved reimbursement for InSightec's initial tremor in 6 additional countries
June 5, 2018

InSightec's treatment is now approved in 16 countries in the United States, and in 22 other countries it is also expected to receive approval soon

Insightec of Tirat Hacarmel, which developed a non-invasive system for initial tremor treatment, today announced that CMS, the federal authority that coordinates government health insurance Medicare and Medicaid, has agreed to indemnify its policyholders for using InSightec's device to treat initial tremors.

To date, treatment has been practiced in ten states in the United States, mainly in the eastern part of the country. It will now be covered in six other states: Indiana, Iowa, Kansas, Nebraska, Michigan, and Missouri. In addition, 22 other countries have submitted positive approval drafts, and if approved, the number of states in the US where InSightec will be covered by the insurance cover will reach 38 countries, which significantly increases InSightec's potential market share in the United States.

InSightec's revenues in 2017 were $ 32 million, up 28% from 2016. In addition, the company's annual report for 2017 reported orders totaling $ 14 million to 2018.

InSightec has developed a unique system for treating the primary tremor. This is a very common neurological disorder that affects the movement of about one-fifth of all adults over the age of 65. The disorder is characterized by a rhythmic tremor that occurs while performing acts against gravity. The company's treatment is based on focused MRI guided ultrasound technology, which does not emit ionizing radiation. The system uses high-intensity ultrasound waves to destroy the designated brain tissue, all while the patient is fully conscious and under MRI surveillance that provides continuous imaging and treatment control.

The largest fund raising in the medical device industry in Israel
InSightec's system is the first focused ultrasound system in the world to be approved by the FDA in the United States. By the beginning of 2017, more than 1,000 patients had been treated in 40 medical centers around the world. InSightec's technology has been used to treat more than 2,000 patients to date.



STMICROELECTRONICS

InSightec completed a $ 150 million financing round this February. This is apparently the largest off-market venture capital fund undertaken in the Israeli medical device industry. The round was led by the Koch Disruptive Technologies investment fund, owned by Koch Industries, which invested $ 100 million in the company.

Insight has signed marketing agreements with two major health device players: Siemens and GE Healthcare. InSightec intends to expand its ability to treat other neurological diseases such as epilepsy, neuropathy and more.

InSightec is a subsidiary of Elbit Medical, which holds 22% of the company's shares
https://techtime.co.il/2018/06/05/insightec-9/

 

[dani191]

2025/5000

Zebra Medical has received European approval for the algorithm for diagnosing breast cancer
24 May, 2018

The new algorithm is added to the company's automatic diagnosis engine, which is based on deep learning technology. To date, the company has introduced identification capabilities for brain hemorrhages, bone thinning, pulmonary diseases, heart and liver, and more


The Israeli medical meter company Zebra Medical continues to expand the diagnostic capability of its AI engine. The company today announced that it has received regulatory approval in the European Union (CE) for a new algorithm that can identify areas suspected of carcinogens of mammograms. The algorithm will join the company's diagnostic engine, which already includes detection capabilities for brain hemorrhages, depletion, vertebrates and lung, heart and liver diseases.

According to the American Cancer Society, about a quarter of the new cancers detected in women worldwide are breast cancer - more than 1.7 million cases a year.Early detection of the disease significantly affects the ability to treat and prevent the spread of cancer: in cases where the cancer is detected early, the chances of survival range from 80% to 90%. Conversely, if the cancer is detected only at a later stage, mortality rates rise to 76%. In Israel, about 5,000 women are diagnosed each year.

Zebra Medical has developed an open platform that helps doctors and researchers quickly develop new algorithms and diagnoses of medical imaging using a very large database and computing power. The system is based on deep learning, enabling physicians and researchers to perform medical diagnoses based on a large reservoir of imaging images such as X-rays, CT and MRI.



STMICROELECTRONICS

According to the company, its AI engine provides much higher diagnostic accuracy than similar platforms on the market and suffers from a large number of false alarms.Apart from this, the great advantage of the Zebra Medical platform is the low cost of the diagnostic service. Zebra Medical offers its service to health care providers for $ 1 per scan, allowing very large access to special radiology capabilities. To date, the company's analytical engine has been installed in about 50 hospitals around the world and has performed more than a million scans of patients.

"We have taken upon ourselves a great challenge to improve the percentage of early detection of breast cancer," says Zebra Medical Director Elad Benjamin. "The assistance tools for Mammogram experts have been proven to be expensive and inaccurate - we intend to change the situation with this product and its next versions
https://techtime.co.il/2018/05/24/zebra-medical-5/